Lumida
/FUL
⌘K
H.B. Fuller Company

H.B. Fuller Company

FUL
$56.96USD↓-2.47%-1.44 today

MARKET CAP

3.1B

P/E (TTM)

12.6x

FWD P/E

11.5x

DAY RANGE

$57 – $59

52W RANGE

$49
$69

AI Summary

Stalk
StalkMedium

Despite a pronounced Stage 4 decline and active downtrend, mean-reversion eligibility opens a tactical long opportunity. Price is oversold and trading near the early-2025 cycle low support zone, yet remains below declining EMAs. The medium-term bias is Bullish under mean-reversion permission, while short-term timing is neutral pending support absorption. Execution is deferred: stalk around the support region, awaiting confirmation of pullback absorption. Primary risks include a decisive breakdown below support and a false rebound reclaiming the EMAs without real continuation.

  • ↑AMS acquisition to add ~$55M annual revenue in medical adhesives
  • ↑Q2 2026 revenue $667M up 5.8% YoY; organic growth 2.6%
  • ↓Volume decline of 6.6% in HHC segment signals weak end-market demand
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

H.B. Fuller Company (NYSE: FUL) is a global leader in the adhesives, sealants, and specialty chemicals market, primarily serving sectors including construction, automotive, electronics, and medical applications. With a focus on innovation and strategic expansions, the company is pursuing growth through key acquisitions, such as the planned acquisition of Advanced Medical Solutions Group plc, which reflects its aim to capture higher-margin medical markets. H.B. Fuller is well-positioned in the industry, leveraging strong operational capabilities and a dedicated supply chain management strategy amidst a challenging economic landscape.

Bull says

  • ↑AMS acquisition to add ~$55M annual revenue in medical adhesives
  • ↑Q2 2026 revenue $667M up 5.8% YoY; organic growth 2.6%
  • ↑Adj EBITDA $181M (+9% YoY); EBITDA margin 19.1% (+70 bp)
  • ↑Gross profit margin rose to 34.2% on pricing actions
  • ↑Quantum Leap initiative to boost working capital and efficiency
  • ↑High earnings yield (~1.05) and strong balance sheet quality

Bear says

  • ↓Volume decline of 6.6% in HHC segment signals weak end-market demand
  • ↓Net debt/EBITDA at 3.1x post-acquisition elevates financial risk
  • ↓Ongoing supply-chain disruptions and inflation squeeze input costs
  • ↓Sensitive to interest rates; construction segment faces headwinds
  • ↓Negative profitability trends and weak growth indicators raise caution
  • ↓Margin risk if raw material inflation outpaces pricing power

Investment themes with FUL

High Dividend Yield↑ +0.32%

Companies paying above-average dividends

AVGO · JPM · XOM

Earnings Call · Q2 2025 · Mgmt. Guidance

Updated 06-30-2026neutral

Transcript signals

Bull points

  • Before we begin, let me remind everyone that our comments today will include references to certain non-GAAP financial measures.
  • Looking forward, we talked about the fact that with this footprint consolidation, you know, we're going to have about $50 million, $40 million, I guess, is the number of incremental CapEx this year. Probably a similar number next year.
  • FlexPak in particular is growing in some of the more developing nations in the world faster, like Latin America, India, parts of Asia.

Bear points

  • we're a little bit behind in terms of capital spending year-to-date versus our budget. I would expect we'll close that gap in the back half of the year
  • overall what we experienced was really just slightly negative to flat volume throughout. There was not a big differentiation from one month to the next.
  • we experienced more of this pause in the electronics market. I think you'll see that extend for a couple more months before the actual improvement in volumes in electronics in Asia picks up because of the new designs that we have, that we've become a part of.
Read full transcript analysis ›